

## Incyte Corporation (INCY)

**\$89.73** (As of 09/08/20)

Price Target (6-12 Months): **\$94.00**

Long Term: 6-12 Months

**Zacks Recommendation:**

**Neutral**

(Since: 06/03/20)

Prior Recommendation: Underperform

Short Term: 1-3 Months

**Zacks Rank: (1-5)**

**3-Hold**

Zacks Style Scores:

VGM:B

Value: C

Growth: A

Momentum: C

### Summary

Incyte's performance in the year so far has been impressive as demand for Jakafi in all three approved indications (polycythemia vera, myelofibrosis and the recent label expansion in acute GVHD) continues to boost sales. The company's efforts to diversify its revenue base are encouraging as well and the label expansion of Jakafi in additional indications will further boost sales. Incyte's efforts to develop its pipeline forming strategic collaborations are positive. The recent approval of Pemazyre, Monjuvi (with MorphoSys) and Tabrecta (with Novartis) will bring additional sales. However, pipeline setbacks are concerning. Moreover, the company is highly dependent on Jakafi for a major chunk of revenues. The recently-approved therapies will pose stiff competition to Jakafi and affect sales. Shares have outperformed the industry in the past year.

### Price, Consensus & Surprise



### Data Overview

52-Week High-Low **\$110.37 - \$62.48**

20-Day Average Volume (Shares) **939,045**

Market Cap **\$19.6 B**

Year-To-Date Price Change **2.8%**

Beta **1.07**

Dividend / Dividend Yield **\$0.00 / 0.0%**

Industry **Medical - Biomedical and Genetics**

Zacks Industry Rank **Bottom 25% (187 out of 251)**

Last EPS Surprise **61.0%**

Last Sales Surprise **15.5%**

EPS F1 Estimate 4-Week Change **0.0%**

Expected Report Date **11/03/2020**

Earnings ESP **0.0%**


P/E TTM **NA**

P/E F1 **NA**

PEG F1 **NA**

P/S TTM **8.2**

### Sales and EPS Growth Rates (Y/Y %)



### Sales Estimates (millions of \$)

|      | Q1    | Q2    | Q3    | Q4    | Annual* |
|------|-------|-------|-------|-------|---------|
| 2021 | 622 E | 693 E | 728 E | 808 E | 2,825 E |
| 2020 | 569 A | 688 A | 623 E | 660 E | 2,527 E |
| 2019 | 498 A | 530 A | 552 A | 579 A | 2,159 A |

### EPS Estimates

|      | Q1        | Q2       | Q3       | Q4       | Annual*   |
|------|-----------|----------|----------|----------|-----------|
| 2021 | \$0.77 E  | \$0.91 E | \$0.97 E | \$1.22 E | \$3.80 E  |
| 2020 | -\$2.86 A | \$1.24 A | \$0.73 E | \$0.76 E | -\$0.29 E |
| 2019 | \$0.62 A  | \$0.75 A | \$0.82 A | \$0.65 A | \$2.83 A  |

\*Quarterly figures may not add up to annual.

The data in the charts and tables, including the Zacks Consensus EPS and Sales estimates, is as of 09/08/2020. The reports text is as of 09/09/2020.

## Overview

Wilmington, DE-based Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland.

Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ("PV"), who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older. While Incyte markets the drug in the United States, it is marketed by Novartis as Jakavi outside the country. Jakafi sales came in at \$1.7 billion in 2019, thereby contributing 78% to total revenues.

The company's second JAK1 and JAK2 inhibitor, Olumiant (baricitinib, JAK1/JAK2 inhibitor) was approved in the EU in Feb 2017 for rheumatoid arthritis (RA). Incyte is co-developing Olumiant with Eli Lilly. In June 2018, the FDA approved the 2mg dose of baricitinib as Olumiant for the treatment of adults with RA. The approval brings another source of income for Incyte as royalties.

In Jun 2016, Incyte entered into a share purchase agreement with ARIAD under which it gained the latter's European business and the rights to Iclusig in the EU and 22 other countries including Switzerland, Norway, Turkey, Israel and Russia. Revenues for 2019 came in at \$2.2 billion, up from \$1.9 billion in 2018.



Source: Zacks Investment Research

## Reasons To Buy:

- ▲ **Share Price Performance:** Incyte's stock has outperformed the industry in the past one year.
- ▲ **Jakafi Driving Growth:** Jakafi continues to drive growth for the company on label expansions. It became the first FDA-approved JAK inhibitor for any indication, and the first and only product to be approved by the FDA for the treatment of MF and PV — rare blood cancers. Jakafi is the only treatment to provide consistent hematocrit control, spleen volume reduction and complete hematological remission by targeting the overactive JAK pathway. Its label has been updated several times since approval, which has boosted Incyte's sales. We note that Jakafi enjoys the Orphan Drug status in the United States for MF, PV and essential thrombocythemia. The drug also has a long patent life that runs until late 2027.

Key growth driver, Jakafi, has been performing well. Incyte's efforts to develop its pipeline are also encouraging.

In order to expand the patient population and increase the commercial potential of the drug, the company is working on expanding the drug's label further. The FDA recently approved Jakafi for the treatment of steroid-refractory acute GVHD in adult and pediatric patients aged 12 years or older. This is the third indication, for which the drug has been approved in the United States. The label expansion of the drug will further boost sales. Meanwhile, REACH2 and REACH3, evaluating steroid-refractory acute and steroid-refractory chronic graft-versus-host disease, respectively, are ongoing in collaboration with Novartis. REACH2, the phase III study evaluating Jakafi in patients with steroid-refractory acute GVHD, met its primary endpoint of superior overall response. An Independent Data Monitoring Committee (IDMC) recommended that the phase III REACH3 trial should continue without modification following an interim efficacy and safety analysis. REACH3 study, evaluating ruxolitinib in patients with steroid-refractory GVHD also met its primary endpoint of ORR at month 6 and both key secondary endpoints (modified Lee symptom scale and failure-free survival).

Moreover, the cream formulation is currently in phase III development for the treatment of patients with mild to moderate atopic dermatitis (TRuE-AD). It is also being evaluated for the treatment of adolescents and adults with vitiligo (TRuE-V). Both the TRuE-AD1 and TRuE-AD2 phase III studies of ruxolitinib cream in patients with mild-to-moderate atopic dermatitis are proceeding as planned and the NDA submission is expected at the end of 2020. Incyte plans to initiate pivotal trials of the combination of ruxolitinib and pascalisib as both first-line therapy for MF patients and MF patients with an inadequate response to ruxolitinib monotherapy.

Meanwhile, Incyte initiated a phase III study, RUXCOVID, to evaluate the efficacy and safety of Jakafi plus standard-of-care (SoC) compared to SoC therapy alone in patients with COVID-19-associated cytokine storm. The company is also opening a second phase III study in the United States to evaluate the efficacy and safety of Jakafi plus SoC compared to SoC therapy alone in COVID-19 patients on mechanical ventilation and who have acute respiratory distress syndrome (ARDS), a type of respiratory failure characterized by rapid onset of widespread inflammation in the lungs.

- ▲ **Approval of Additional Drugs Bode Well:** Incyte's pipeline is highly encouraging. The company has several candidates in early-to mid-stage development, including both targeted therapies and immune therapies that are being developed in oncology and outside oncology. The FDA recently approved pemigatinib, a kinase inhibitor indicated for the treatment of adults with previously-treated, unresectable, locally-advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement as detected by an FDA-approved test. The candidate has been approved under the brand name, Pemazyre. Approval of new drugs will reduce Incyte's dependence on lead drug, Jakafi. The marketing authorization application (MAA) seeking approval for pemigatinib in Europe is under review with the European Medicines Agency (EMA).

Pemazyre is also being evaluated in other studies for various other indications — myeloproliferative neoplasms and in previously-treated, locally-advanced/metastatic or surgically unresectable solid tumor malignancies. A phase III study is also ongoing to evaluate the drug as a first-line treatment for patients with cholangiocarcinoma with FGFR2 fusions or rearrangements. It is also being evaluated in a phase II study in combination with Keytruda and as monotherapy in patients with previously-untreated, metastatic or unresectable bladder cancer harboring FGFR3 mutations or fusions/rearrangements, who are not eligible to receive cisplatin.

The FDA recently approved Taltrex (capmatinib) for treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as detected by an FDA-approved test. Novartis has exclusive worldwide development and commercialization rights to Taltrex and the FDA approval of the drug triggers \$70 million in milestone payments from Novartis. Incyte is also eligible to receive 12-14% royalties on net sales of Taltrex from Novartis. The drug was recently approved in Japan. In July 2020, the FDA approved Monjuvi (tafasitamab-cxix), an Fc-engineered anti-CD19 antibody, in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and who are not eligible for autologous stem cell transplant (ASCT). Incyte and MorphoSys will co-commercialize Monjuvi in the United States. These new approvals will bring additional source of income for the company.

Preparations are ongoing to initiate the phase III POD1UM-304 study of retifanlimab (formerly INCMGA0012) in combination with platinum-based chemotherapy as a first-line treatment for patients with non-small cell lung cancer (NSCLC).

- ▲ **Encouraging Collaborations:** Incyte has two major agreements with Novartis and Lilly. The 2009 agreement with Novartis includes Jakafi (excluding topical formulations). Per the agreement, Incyte is marketing Jakafi in the United States while Novartis is responsible for the same outside the United States. The deal with Eli Lilly gives the latter exclusive worldwide development and commercialization rights to Olumiant. The FDA approval of Olumiant has triggered a \$100 million milestone payment from Lilly. However, Incyte has elected to not participate in the development of baricitinib in order to reallocate capital, over time, to other promising internal projects. Nevertheless, it will continue to receive royalties on global net sales of Olumiant, pursuant to the terms of its agreement with Lilly. The collaboration and license agreement with MorphoSys for the development and commercialization of tafasitamab became effective in March 2020. The FDA has granted Priority Review to tafasitamab in combination with lenalidomide for the treatment of relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), and set a PDUFA goal date of Aug 30, 2020.

---

▲ **Favorable Debt Profile:** As of Jun 30, 2020, Incyte' total debt to total capital ratio stood at 2.5X, which compares favorably to the industry's 50.9X. A lower ratio indicates lower financial risk and vice versa. The company has a sound cash position too with cash, equivalents and marketable securities of \$1.0 billion with a long-term debt of \$32 million.

---

---

## Reasons To Sell:

- ▼ **Overdependence on Jakafi for Growth:** Incyte's dependence on a single product, Jakafi for growth is concerning. Lower-than-expected sales would be a huge setback for the company. While we are positive on the company's efforts to expand Jakafi's label, any development/regulatory setback could pull down the stock significantly.
- ▼ **Pipeline Setbacks:** Though we are pleased with Incyte's broad pipeline, the candidates still have to go a long way before hitting the market. Any hiccup in the development process or adverse study results may weigh heavily on the stock and hamper the company's growth progress.

The phase III GRAVITAS-301, evaluating itacitinib in combination with corticosteroids in patients with treatment-naïve (first-line) acute GVHD, did not meet the primary endpoint of overall response rate (ORR) at day 28 compared to placebo plus corticosteroids. Incyte earlier suffered a setback with epacadostat. The external Data Monitoring Committee (eDMC) review of the pivotal phase III study, ECHO-301, evaluating epacadostat in combination with Keytruda in patients with unresectable or metastatic melanoma determined that the study did not meet the primary endpoint of improving progression-free survival in the overall population compared to pembrolizumab monotherapy. Consequently, based on the disappointing data and the recommendation of the eDMC, Incyte stopped the study to enable patients and their physicians to consider alternative therapeutic options.

- ▼ **Stiff Competition:** The FDA approval of Inrebic for the treatment of adult patients with intermediate-2 or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis will increase competition for Jakafi. Additionally, Jakafi is likely to face competition from generics. Also, Iclusig faces intense competition. Meanwhile, the oncology market is attracting a lot of attention, with several companies inking deals to tap into this high revenue-potential market.

Overdependence on Jakafi is concerning. Also, most of its pipeline candidates are in early-to-mid stages of development, which translates into a long way to approval.

## Last Earnings Report

### Incyte Beats on Q2 Earnings and Sales on Strong Jakafi

Incyte reported an adjusted earnings of \$1.24 per share, easily beating the Zacks Consensus Estimate of earnings of 77 cents. The company had reported adjusted earnings of 75 cents in the year-ago quarter.

Including milestones and contracts, revenues came in at \$688.04 million, which grew 30% year over year and beat the Zacks Consensus Estimate of \$599.45 million.

Quarter Ending 06/2020

| Report Date      | Aug 04, 2020 |
|------------------|--------------|
| Sales Surprise   | 15.50%       |
| EPS Surprise     | 61.04%       |
| Quarterly EPS    | 1.24         |
| Annual EPS (TTM) | -0.15        |

### Quarter in Detail

Total product-related revenues came in at \$593 million, up 16% from the year-ago quarter. Jakafi revenues came in at \$473.7 million, increasing 16% from the year-ago quarter and beating the Zacks Consensus Estimate of \$471 million. Robust demand for Jakafi in all three approved indications drove revenues.

Net product revenues of Iclusig amounted to \$22.8 million, down from \$24.4 million in the year-ago quarter.

Jakavi (name outside the United States) royalty revenues from Novartis AG for commercialization in ex-U.S. markets grew 16% to \$66.2 million. Olumiant's product royalty revenues from Eli Lilly came in at \$25.8 million, up 35%.

R&D expenses were \$254.1 million, down from \$261.7 million in the year-ago quarter. SG&A expenses amounted to \$104.4 million, up from \$93.1 million in the prior-year quarter.

### 2020 Guidance Reaffirmed

The company maintained its previously-provided guidance for 2020. The company expects Jakafi revenues of \$1,880-\$1,950 million for 2020. Iclusig revenues are projected around \$100-\$105 million.

### Pipeline Update

In July, the FDA granted approval to Monjuvi (tafasitamab-cxix), an Fc-engineered anti-CD19 antibody, in combination with Revlimid for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) and who are not eligible for autologous stem cell transplant (ASCT). Please note that Incyte entered into a global collaboration with MorphoSys for the development and commercialization of tafasitamab. Incyte and MorphoSys will co-commercialize Monjuvi in the United States.

In May 2020, Incyte and partner Novartis obtained FDA approval of Tabrecta (capmatinib) for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have a mutation that leads to MET exon 14 skipping (METex14) as detected by an FDA-approved test.

In April, the FDA approved Incyte's selective FGFR inhibitor, Pemazyre (pemigatinib), for the treatment of adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or other rearrangement as detected by an FDA-approved test.

The REACH3 study, evaluating ruxolitinib in patients with steroid-refractory chronic graft-versus-host disease (GVHD), met its primary endpoint of overall response rate (ORR) at month 6 and both key secondary endpoints (modified Lee symptom scale and failure-free survival). The company also plans to file a new drug application seeking approval for ruxolitinib cream, a new formulation of its key drug Jakafi, as a treatment for mild-to-moderate atopic dermatitis by the end of 2020.

## Recent News

### Monjuvi Gets FDA Approval – July 31

Incyte and MorphoSys announced that the FDA has approved Monjuvi (tafasitamab-cxix) in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

### Reports Positive Data on Jakafi – July 23

Incyte announced that the late-stage study, REACH3, evaluating Jakafi in patients with moderate or severe steroid-refractory or steroid dependent chronic graft-versus-host disease (GVHD) met its primary endpoint of superior overall response rate (ORR) at week 24 compared to best available therapy (BAT). In addition, the study met both key secondary endpoints, significantly improving failure-free survival (FFS) and patient-reported symptoms assessed by the modified Lee chronic GVHD symptom scale (mLSS).

### Approval of Tabrecta in Japan – June 29

Incyte announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) approved Tabrecta (capmatinib) for MET exon 14 skipping (METex14) mutation-positive advanced and/or recurrent unresectable non-small cell lung cancer (NSCLC). Tabrecta is approved for first-line and previously treated patients, regardless of prior treatment type.

Tabrecta is the third Incyte-discovered medicine to receive approval in Japan. Its partner Novartis has exclusive worldwide development and commercialization rights to Tabrecta. The approval of the drug in Japan triggers a \$20-million milestone payment to Incyte. The company is also eligible to receive 12-14% royalties on global net sales of Tabrecta by Novartis.

## Valuation

Incyte's shares are up 5% in the year-to-date period and 17.7% over the trailing 12-month period. Stocks in the Zacks sub-industry and the Zacks Medical sector are down 3.4% and 2.5% in the year-to-date period, respectively. Over the past year, the Zacks sub-industry is up 9.8% while the sector is up 6%.

The S&P 500 index is up 3.6% in the year-to-date period and 12.5% in the past year.

The stock is currently trading at 7.18X forward 12-month sales per share which compares to 2.7X for the Zacks sub-industry, 2.72X for the Zacks sector and 4.08X for the S&P 500 Index.

Over the past five years, the stock has traded as high as 27.64X and as low as 5.35X, with a 5-year median of 9.97X. Our Neutral recommendation indicates that the stock will perform in-line with the market. Our \$94 price target reflects 7.5X forward 12-month sales per share.

The table below shows summary valuation data for INCY

| Valuation Multiples - INCY |               |       |              |        |         |
|----------------------------|---------------|-------|--------------|--------|---------|
|                            |               | Stock | Sub-Industry | Sector | S&P 500 |
| P/S F12M                   | Current       | 7.18  | 2.7          | 2.72   | 4.08    |
|                            | 5-Year High   | 27.64 | 3.26         | 3.25   | 4.29    |
|                            | 5-Year Low    | 5.35  | 1.93         | 2.23   | 3.11    |
|                            | 5-Year Median | 9.97  | 2.71         | 2.89   | 3.66    |
| P/B TTM                    | Current       | 8.37  | 2.96         | 3.79   | 5.73    |
|                            | 5-Year High   | 426.7 | 5.87         | 5.07   | 6.17    |
|                            | 5-Year Low    | 5.24  | 2.07         | 2.95   | 3.75    |
|                            | 5-Year Median | 11.33 | 3.86         | 4.29   | 4.83    |

As of 09/08/2020

Source: Zacks Investment Research

## Industry Analysis Zacks Industry Rank: Bottom 25% (187 out of 251)



Source: Zacks Investment Research

## Top Peers

| Company (Ticker)                                   | Rec        | Rank |
|----------------------------------------------------|------------|------|
| Emergent Biosolutions Inc. (EBS)                   | Outperform | 1    |
| Horizon Therapeutics Public Limited Company (HZNP) | Outperform | 1    |
| QIAGEN N.V. (QGEN)                                 | Outperform | 1    |
| Alkermes plc (ALKS)                                | Neutral    | 3    |
| SWEDISH ORP BIO (BIOVF)                            | Neutral    | 4    |
| BioMarin Pharmaceutical Inc. (BMRN)                | Neutral    | 4    |
| Bristol Myers Squibb Company (BMY)                 | Neutral    | 3    |
| SINO PHARMACEUT (SBMFF)                            | Neutral    | 3    |

The positions listed should not be deemed a recommendation to buy, hold or sell.

| Industry Comparison Industry: Medical - Biomedical And Genetics |          |            |           | Industry Peers |           |            |
|-----------------------------------------------------------------|----------|------------|-----------|----------------|-----------|------------|
|                                                                 | INCY     | X Industry | S&P 500   | BMRN           | BMY       | QGEN       |
| Zacks Recommendation (Long Term)                                | Neutral  | -          | -         | Neutral        | Neutral   | Outperform |
| Zacks Rank (Short Term)                                         | 3        | -          | -         | 4              | 3         | 1          |
| VGM Score                                                       | B        | -          | -         | B              | B         | D          |
| Market Cap                                                      | 19.62 B  | 274.42 M   | 22.91 B   | 13.51 B        | 132.44 B  | 10.99 B    |
| # of Analysts                                                   | 6        | 3          | 14        | 9              | 7         | 5          |
| Dividend Yield                                                  | 0.00%    | 0.00%      | 1.66%     | 0.00%          | 3.08%     | 0.00%      |
| Value Score                                                     | C        | -          | -         | D              | B         | D          |
| Cash/Price                                                      | 0.08     | 0.25       | 0.07      | 0.10           | 0.16      | 0.08       |
| EV/EBITDA                                                       | 33.26    | -3.49      | 12.82     | 413.21         | 22.71     | 42.77      |
| PEG F1                                                          | NA       | 1.69       | 2.90      | NA             | 1.09      | 1.04       |
| P/B                                                             | 8.37     | 3.77       | 3.15      | 4.17           | 2.69      | 4.19       |
| P/CF                                                            | 35.86    | 16.45      | 12.45     | 116.91         | 13.33     | 18.16      |
| P/E F1                                                          | NA       | 23.24      | 21.08     | 54.68          | 9.38      | 23.24      |
| P/S TTM                                                         | 8.22     | 14.60      | 2.43      | 7.31           | 3.80      | 6.82       |
| Earnings Yield                                                  | -0.32%   | -13.57%    | 4.52%     | 1.83%          | 10.66%    | 4.31%      |
| Debt/Equity                                                     | 0.01     | 0.02       | 0.70      | 0.33           | 0.85      | 0.53       |
| Cash Flow (\$/share)                                            | 2.50     | -1.08      | 6.93      | 0.64           | 4.39      | 2.66       |
| Growth Score                                                    | A        | -          | -         | A              | A         | D          |
| Historical EPS Growth (3-5 Years)                               | 52.48%   | 19.03%     | 10.41%    | NA             | 23.36%    | 9.09%      |
| Projected EPS Growth (F1/F0)                                    | -110.25% | 15.73%     | -4.73%    | 46.47%         | 32.99%    | 45.17%     |
| Current Cash Flow Growth                                        | 132.41%  | 12.13%     | 5.22%     | 200.25%        | 36.74%    | 9.25%      |
| Historical Cash Flow Growth (3-5 Years)                         | 140.30%  | 7.73%      | 8.49%     | 27.84%         | 22.46%    | 5.76%      |
| Current Ratio                                                   | 3.73     | 6.07       | 1.35      | 3.26           | 1.47      | 1.71       |
| Debt/Capital                                                    | 1.34%    | 3.34%      | 42.95%    | 24.90%         | 45.99%    | 34.82%     |
| Net Margin                                                      | -8.00%   | -205.02%   | 10.25%    | 6.62%          | -1.61%    | 0.86%      |
| Return on Equity                                                | -8.06%   | -58.99%    | 14.59%    | 4.37%          | 28.47%    | 15.85%     |
| Sales/Assets                                                    | 0.76     | 0.19       | 0.50      | 0.38           | 0.31      | 0.31       |
| Projected Sales Growth (F1/F0)                                  | 17.06%   | 0.00%      | -1.42%    | 9.91%          | 60.20%    | 15.78%     |
| Momentum Score                                                  | C        | -          | -         | F              | F         | F          |
| Daily Price Change                                              | -0.84%   | 0.00%      | -1.95%    | -1.99%         | -2.37%    | 1.32%      |
| 1-Week Price Change                                             | -3.63%   | -4.93%     | -1.28%    | -0.50%         | -3.88%    | -5.98%     |
| 4-Week Price Change                                             | -3.50%   | -6.18%     | -1.93%    | -36.24%        | -7.29%    | -0.92%     |
| 12-Week Price Change                                            | -6.07%   | -8.15%     | 3.73%     | -30.04%        | 2.58%     | 12.81%     |
| 52-Week Price Change                                            | 15.17%   | 3.79%      | -0.29%    | 1.22%          | 20.53%    | 44.03%     |
| 20-Day Average Volume (Shares)                                  | 939,045  | 265,535    | 1,798,028 | 4,117,075      | 8,635,366 | 1,752,341  |
| EPS F1 Estimate 1-Week Change                                   | 0.00%    | 0.00%      | 0.00%     | 0.00%          | 0.00%     | 0.00%      |
| EPS F1 Estimate 4-Week Change                                   | 0.00%    | 0.00%      | 0.00%     | -32.77%        | -0.02%    | -0.67%     |
| EPS F1 Estimate 12-Week Change                                  | 13.18%   | 1.41%      | 3.98%     | -17.24%        | 1.42%     | 19.65%     |
| EPS Q1 Estimate Monthly Change                                  | 0.00%    | 0.00%      | 0.00%     | -10.00%        | -0.34%    | -1.34%     |

Source: Zacks Investment Research

---

## Zacks Stock Rating System

We offer two rating systems that take into account investors' holding horizons: Zacks Rank and Zacks Recommendation. Each provides valuable insights into the future profitability of the stock and can be used separately or in combination with each other depending on your investment style.

### Zacks Recommendation

The Zacks Recommendation aims to predict performance over the next 6 to 12 months. The foundation for the quantitatively determined Zacks Recommendation is trends in the company's estimate revisions and earnings outlook. The Zacks Recommendation is broken down into 3 Levels; Outperform, Neutral and Underperform. Unlike many Wall Street firms, we maintain a balance between the number of Outperform and Neutral recommendations. Our team of 70 analysts are fully versed in the benefits of earnings estimate revisions and how that is harnessed through the Zacks quantitative rating system. But we have given our analysts the ability to override the Zacks Recommendation for the 1200 stocks that they follow. The reason for the analyst over-rides is that there are often factors such as valuation, industry conditions and management effectiveness that a trained investment professional can spot better than a quantitative model.

### Zacks Rank

The Zacks Rank is our short-term rating system that is most effective over the one- to three-month holding horizon. The underlying driver for the quantitatively-determined Zacks Rank is the same as the Zacks Recommendation, and reflects trends in earnings estimate revisions.

---

### Zacks Style Scores

The Zacks Style Score is as a complementary indicator to the Zacks rating system, giving investors a way to focus on the highest rated stocks that best fit their own stock picking preferences.

Academic research has proven that stocks with the best Value, Growth and Momentum characteristics outperform the market. The Zacks Style Scores rate stocks on each of these individual styles and assigns a rating of A, B, C, D and F. We also produce the VGM Score (V for Value, G for Growth and M for Momentum), which combines the weighted average of the individual Style Scores into one score. This is perfectly suited for those who want their stocks to have the best scores across the board.

|                |   |
|----------------|---|
| Value Score    | C |
| Growth Score   | A |
| Momentum Score | C |
| VGM Score      | B |

As an investor, you want to buy stocks with the highest probability of success. That means buying stocks with a Zacks Recommendation of Outperform, which also has a Style Score of an A or a B.

---

## Disclosures

**This report contains independent commentary to be used for informational purposes only. The analysts contributing to this report do not hold any shares of this stock. The analysts contributing to this report do not serve on the board of the company that issued this stock. The EPS and revenue forecasts are the Zacks Consensus estimates, unless indicated otherwise on the reports first page.** Additionally, the analysts contributing to this report certify that the views expressed herein accurately reflect the analysts personal views as to the subject securities and issuers. ZIR certifies that no part of the analysts compensation was, is, or will be, directly or indirectly, related to the specific recommendation or views expressed by the analyst in the report.

Additional information on the securities mentioned in this report is available upon request. This report is based on data obtained from sources we believe to be reliable, but is not guaranteed as to accuracy and does not purport to be complete. Any opinions expressed herein are subject to change.

ZIR is not an investment advisor and the report should not be construed as advice designed to meet the particular investment needs of any investor. Prior to making any investment decision, you are advised to consult with your broker, investment advisor, or other appropriate tax or financial professional to determine the suitability of any investment. This report and others like it are published regularly and not in response to episodic market activity or events affecting the securities industry.

This report is not to be construed as an offer or the solicitation of an offer to buy or sell the securities herein mentioned. ZIR or its officers, employees or customers may have a position long or short in the securities mentioned and buy or sell the securities from time to time. ZIR is not a broker-dealer. ZIR may enter into arms-length agreements with broker-dealers to provide this research to their clients. Zacks and its staff are not involved in investment banking activities for the stock issuer covered in this report.

ZIR uses the following rating system for the securities it covers. **Outperform-** ZIR expects that the subject company will outperform the broader U.S. equities markets over the next six to twelve months. **Neutral-** ZIR expects that the company will perform in line with the broader U.S. equities markets over the next six to twelve months. **Underperform-** ZIR expects the company will underperform the broader U.S. equities markets over the next six to twelve months.

No part of this report can be reprinted, republished or transmitted electronically without the prior written authorization of ZIR.

---

## Additional Disclosure

This material represents an assessment of the market and economic environment at a specific point in time and is not intended to be a forecast of future events, or a guarantee of future results. Forward-looking statements are subject to certain risks and uncertainties. Any statements that refer to expectations, projections or characterizations of future events or circumstances, including any underlying assumptions, are forward-looking statements. Actual results, performance, or achievements may differ materially from those expressed or implied.

**Returns quoted represent past performance which is no guarantee of future results.** Investment returns and principal value will fluctuate so that when shares are redeemed, they may be worth more or less than their original cost. Current performance may be higher or lower than the performance shown.

Investing involves risk; principal loss is possible. There is no guarantee that companies that can issue dividends will declare, continue to pay or increase dividends.

## Glossary of Terms and Definitions

**52-Week High-Low:** The range of the highest and lowest prices at which a stock has traded during the past year. This range is determined based on the stock's daily closing price which may differ from the intra-day high or low. Many investors use it as a technical indicator to determine a stock's current value and future price movement. The idea here is that if price breaks out from the 52-week range, in either direction, the momentum may continue in the same direction.

**20-Day Average Volume (Shares):** The average number of shares of a company traded in a day over the last 20 days. It is a direct indication of a security's overall liquidity. The higher the average daily trading volume, the easier it is to enter or exit the stock at a desired price with more buyers and sellers being available.

**Daily Price Change:** This is the percentage difference between a trading day's closing price and the prior trading day's closing price. This item is updated at 9 p.m. EST each day.

**1-Week Price Change:** This is the percentage change in a stock's closing price over the last 5 trading days. This change reflects the collective buying and selling sentiment over the 1-week period.

A strong weekly price increase for the stock, especially when accompanied by increased volume, is an indication of it gaining momentum.

**4-Week Price Change:** This is the percentage change in a stock's closing price over the last 20 trading days or past 4 weeks. This is a medium-term price change metric and an indication of the stock gaining momentum.

**12-Week Price Change:** This is the percentage change of a stock's closing price over the last 60 trading days or past 12 weeks. Similar to 4-week price change, this is a medium-term price change metric. It shows whether a stock has been enjoying strong investor demand, or if it has been in consolidation, or distress over this period.

**52-Week Price Change:** This is the percentage change in a stock's closing price over the last 260 trading days or past 52 weeks. This long-term price change metric is a good reference point for investors. Some investors seek stocks with the best percentage price change over the last 52 weeks, expecting the momentum to continue.

**Market Cap:** The number of outstanding common shares of a company times its latest price per share. This figure represents a company's size, which indicates various characteristics, including price stability and risk, in which investors could be interested.

**Year-To-Date Price Change:** Change in a stock's daily closing price in the period of time beginning the first day of the current calendar year through to the previous trading day.

**# of Analysts:** Number of EPS estimates used in calculating the current-quarter consensus. These estimates come from the brokerage analysts tracking this stock. However, the number of such analysts tracking this stock may not match the number of estimates, as all brokerage analysts may not come up with an estimate or provide it to us.

**Beta:** A measure of risk commonly used to compare the volatility of a stock to the overall market. The S&P 500 Index is the base for calculating beta and carries a value of 1. A stock with beta below 1 is less risky than the market as a whole. And a stock with beta above 1 is riskier.

**Dividend:** The portion of earnings a company is expected to distribute to its common shareholders in the next 12 months for each share they own. Dividends are usually paid quarterly. Dividend payments reflect positively on a company and help maintain investors' trust. Investors typically find dividend-paying stocks appealing because the dividend adds to any market price appreciation to result in higher return on investment (ROI). Moreover, a steady or increasing dividend payment provides investors a cushion in a down market.

**Dividend Yield:** The ratio of a company's annual dividend to its share price. The annual dividend used in the ratio is calculated based on the most recent dividend paid by the company. Dividend yield is an estimate of the dividend-only return from a stock in the next 12 months. Since dividend itself doesn't change frequently, dividend yield usually changes with a stock's price movement. As a result, often an unusually high dividend yield is a result of weak stock price.

**S&P 500 Index:** The Standard & Poor's 500 (S&P 500) Index is an unmanaged group of securities considered to be representative of the stock market in general. It is a market-capitalization-weighted index of stocks of the 500 largest U.S. companies. Each stock's weight in the index is proportionate to its market value.

**Industry:** One of the 250+ groups that Zacks classifies all stocks into based on the nature of business. These groups are termed as expanded (aka "X") industries and map to their respective (economic) sectors; Zacks has 16 sectors.

---

**Zacks Industry Rank:** The Zacks Industry Rank is determined by calculating the average Zacks Rank for all stocks in the industry and then assigning an ordinal rank to it. For example, an industry with an average Zacks Rank of 1.6 is better than an industry with an average Zacks Rank of 2.3. So, the industry with the better average Zacks Rank would get a better Zacks Industry Rank. If an industry has the best average Zacks Rank, it would be considered the top industry (1 out of 250+), which would place it at the top 1% of Zacks-ranked industries. Studies have shown that roughly half of a stock's price movement can be attributed to the industry group it belongs to. In fact, the top 50% of Zacks-ranked industries outperforms the bottom 50% by a factor of more than 2 to 1.

**Last EPS Surprise:** The percentage deviation of a company's last reported earnings per share from the Zacks Consensus Estimate. Companies with a positive earnings surprise are more likely to surprise again in the future (or miss again if they recently missed).

**Last Sales Surprise:** The percentage deviation of a company's last reported sales from the Zacks Consensus Estimate.

**Expected Report Date:** This is an estimated date of a company's next earnings release. The information originated or gathered by Zacks Investment Research from its information providers or publicly available sources is the basis of this estimate.

**Earnings ESP:** The Zacks Earnings ESP compares the Most Accurate Estimate to the Zacks Consensus Estimate for the yet-to-be reported quarter. The Most Accurate Estimate is the most recent version of the Zacks Consensus EPS Estimate. The idea here is that analysts revising their estimates closer to an earnings release have the latest information, which could potentially be more accurate than what they and others contributing to the consensus had predicted earlier. Thus, a positive or negative Earnings ESP reading theoretically indicates the likely deviation of the actual earnings from the consensus estimate. However, the model's predictive power is significant for positive ESP readings only. A positive Earnings ESP is a strong predictor of an earnings beat, particularly when combined with a Zacks Rank #1 (Strong Buy), #2 (Buy) or #3 (Hold). Our research shows that stocks with this combination produce a positive surprise nearly 70% of the time.

**Periods:**

**TTM:** Trailing 12 months. Using TTM figures is an effective way of analyzing the most-recent financial data in an annualized format that helps neutralize the effects of seasonality and other quarter-to-quarter variation.

**F1:** Current fiscal year. This period is used to analyze the estimates for the ongoing full fiscal year.

**F2:** Next fiscal year. This period is used to analyze the estimates for the next full fiscal year.

**F12M:** Forward 12 months. Using F12M figures is an effective way of analyzing the near-term (the following four unreported quarters) estimates in an annualized manner. Instead of typically representing estimates for the full fiscal year, which may not represent the nitty-gritty of each quarter, F12M figures suggest an all-inclusive annualized estimate for the following four quarters. The annualization helps neutralize the potential effects of seasonality and other quarter-to-quarter variations.

**P/E Ratio:** The price-to-earnings ratio measures a company's current market price per share relative to its earnings per share (EPS). Usually, the trailing-12-month (TTM) EPS, current-fiscal-year (F1) EPS estimate, or forward-12-month (F12M) EPS estimate is used as the denominator. In essence, this ratio shows what the market is willing to pay today for each dollar of EPS. In other words, this ratio gives a sense of what the relative value of the company is at the already reported level of earnings or at a future level of earnings.

It is one of the most widely-used multiples for determining the value of a company and helps comparing its valuation with that of a competitor, the industry group or a benchmark.

**PEG Ratio:** The price/earnings to growth ratio is a stock's P/E ratio using current fiscal year (F1) EPS estimate divided by its expected EPS growth rate over the coming 3 to 5 years. This ratio essentially determines a stock's value by factoring in the company's expected earnings growth and is thus believed to provide a more complete picture than just the P/E ratio, particularly for faster-growing companies.

**P/S Ratio:** The price-to-sales ratio is calculated as a company's current price per share divided by trailing 12 months (TTM) sales or revenues per share. This ratio shows what the market is willing to pay today for each dollar of TTM sales per share. The P/S ratio is at times the only valuation metric when the company has yet to become profitable.

**Cash/Price Ratio:** The cash-to-price ratio or Cash Yield is calculated as cash and marketable securities per share divided by the company's current share price. Like the earnings yield, which shows the anticipated yield (or return) on a stock from earnings for each dollar invested, the cash yield does the same, with cash being the source of return instead of earnings. For example, a cash/price ratio of 0.08 suggests a return of 8% or 8 cents for every \$1 investment.

**EV/EBITDA Ratio:** The EV/EBITDA ratio, also known as Enterprise Multiple, is calculated as a company's enterprise value (market capitalization + value of total long-term debt + book value of preferred shares - cash and marketable securities) divided by EBITDA (earnings before interest, taxes, depreciation and amortization). Usually, trailing-12-month (TTM) or forward-12-month (F12M) EBITDA is used as the denominator.

**EV/Sales Ratio:** The enterprise value-to-sales ratio is calculated as a company's enterprise value (market capitalization + value of total long-term debt + book value of preferred shares - cash and marketable securities) divided by annual sales. It is an expansion of the P/S valuation, which uses market value instead of enterprise value. The EV/Sales ratio is perceived as more accurate than P/S, in part, because the market capitalization does not take a company's debt into account when valuing it.

**EV/CF Ratio:** The enterprise value-to-cash flow ratio is calculated as a company's enterprise value (market capitalization + value of total long-term debt + book value of preferred shares - cash and marketable securities) divided by the trailing-12-month (TTM) operating cash flow. It's a measure of how long it would take to buy the entire business if you were able to use all the company's operating cash flow.

The EV/CF ratio is perceived as more accurate than the P/CF ratio, in part, because the market price does not take a company's debt into account when valuing it.

---

**EV/FCF Ratio:** The enterprise value-to-free cash flow metric compares a company's enterprise value to its trailing-12-month (TTM) free cash flow (FCF). This metric is very similar to the EV/CF ratio, but is considered a more exact measure owing to the fact that it uses free cash flow, which subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available for funding growth activities and payments to shareholders.

**P/EBITDA Ratio:** The P/EBITDA ratio is calculated as a company's per share market value divided by EBITDA (earnings before interest, taxes, depreciation, and amortization). This metric is very similar to the EV/EBITDA ratio, but is considered a little less exact measure as it uses market price, which does not take a company's debt into account. However, since EBITDA is often considered a proxy for cash income, the metric is used as a measure of what the market is willing to pay today for each dollar of the company's cash profitability in the trailing 12 months (TTM) or forward 12 months (F12M).

**P/B Ratio:** The price-to-book ratio is calculated as a company's current price per share divided by its book value (total assets – liabilities – preferred stocks) per share. In short, the book value is how much a company is worth. In other words, it reflects the total value of a company's assets that its common shareholders would receive if it were to be liquidated. So, the P/B ratio indicates whether you're paying higher or lower than what would remain if the company went bankrupt immediately. Investors typically use this metric to determine how a company's stock price stacks up to its intrinsic value.

**P/TB Ratio:** The price-to-tangible-book value ratio is calculated as a the per share market value of a company divided by the value of its tangible assets (total assets – liabilities – preferred stocks – intangible assets) per share. Tangible book value is the same thing as book value except it excludes the value of intangible assets to get a step closer to the baseline value of the company.

**P/CF Ratio:** The price-to-cash flow ratio measures a company's per share market price relative to its trailing-12-month (TTM) operating cash flow per share. This metric is used to determine whether a company is undervalued or overvalued relative to another stock, industry or sector. And like the P/E ratio, a lower number is typically considered better from the value perspective.

One of the reasons why P/CF ratio is often preferred over P/E ratio is the fact that operating cash flow adds back non-cash expenses such as depreciation and amortization to net income. This feature helps valuing stocks that have positive cash flow but are not profitable because of large noncash charges.

**P/FCF Ratio:** The price-to-free cash flow ratio is an extension of P/CF ratio, which uses trailing-12-month (TTM) free cash flow per share instead of operating cash flow per share. This metric is considered a more exact measure than P/CF ratio, as free cash flow subtracts capital expenditures (CAPEX) from a company's total operating cash flow, thereby reflecting the actual cash flow available for funding activities that generate additional revenues.

**Earnings Yield:** The earnings yield is calculated as current fiscal year (F1) EPS estimate divided by the company's current share price. The ratio, which is the inverse of the P/E ratio, measures the anticipated yield (or return) from earnings for each dollar invested in a stock today.

For example, earnings yield for a stock, which is trading at \$35 and expected to earn \$3 per share in the current fiscal year (F1), would be 0.0857 ( $3/35 = 0.0857$ ) or 8.57%. In other words, for \$1 invested in the stock today, the yield from earnings is anticipated to be 8.57 cents.

Investors most commonly compare the earnings yield of a stock to that of a broad market index (such as the S&P 500) and prevailing interest rates, such as the current 10-year Treasury yield. Since bonds and stocks compete for investors' dollars, stock investors typically demand a higher yield for the extra risk they assume compared to investors of U.S. Treasury-backed securities that offer virtually risk-free returns. This additional return is referred to as the risk premium.

**Debt/Equity Ratio:** The debt-to-equity ratio is calculated as a company's total liabilities divided by its shareholder equity. This metric is used to gauge a company's financial leverage. In other words, it is a measure of the degree to which a company is financing its operations through debt versus its own funds. The higher the ratio, the higher the risk for shareholders.

However, this ratio is difficult to compare across industry groups where ideal amounts of debt vary. Some businesses are more capital intensive than others and typically require higher debt to finance their operations. So, a company's debt-to-equity ratio should be compared with other companies in the same industry.

**Cash Flow (\$/share):** Cash flow per share is calculated as operating cash flow (after-tax earnings + depreciation + other non-cash charges) divided by common shares outstanding. It is used by many investors as a measure of a company's financial strength. Since cash flow per share takes into consideration a company's ability to generate cash by adding back non-cash expenses, it is regarded by some as a more accurate measure of a company's financial situation than earnings per share, which could be artificially deflated.

**Current Ratio:** The current ratio or liquidity ratio is a company's current assets divided by its current liabilities. It measures a company's ability to pay short-term obligations. A current ratio that is in line with the industry average or slightly higher is generally considered acceptable. A current ratio that is lower than the industry average would indicate a higher risk of distress or default. A higher number is usually better. However, a very high current ratio compared to the industry average could be an indication of inefficient use of assets by management.

**Debt/Capital Ratio:** Debt-to-capital ratio is a company's total debt (interest-bearing debt + both short- and long-term liabilities) divided its total capital (interest-bearing debt + shareholders' equity). It is a measure of a company's financial leverage. All else being equal, the higher the debt-to-capital ratio, the riskier the stock.

However, this ratio can vary widely from industry to industry, the ideal amount of required debt being different. Some businesses are more capital intensive than others and typically require higher debt to finance their operations. So, a company's debt-to-capital ratio should be compared with the same for its industry.

---

**Net Margin:** Net margin is calculated as net income divided by sales. It shows how much of each dollar in sales generated by a company translates into profit. For example, if a company's net margin is 15%, its net income is 15 cents for every \$1 of sales it makes.

A change in margin can reflect either a change in business conditions, or a company's cost controls, or both. If a company's expenses are growing faster than sales, its net margin will decline. However, different net margin rates are considered good for different industries, so it's better to compare net margin rates of companies in the same industry group.

**Return on Equity:** Return on equity (ROE) is calculated as trailing-12-month net income divided by trailing-12-month average shareholder equity (including reinvested earnings). This metric is considered a measure of how effectively management is using a company's assets to generate profits. For example, if a company's ROE is 10%, it creates 10 cents profits for every \$1 shareholder equity, which is basically the company's assets minus debt. A company's ROE deemed good or bad depends on what's normal for its peers or industry group.

**Sales/Assets Ratio:** The sales-to-assets ratio or asset utilization ratio or asset turnover ratio is calculated as a company's annual sales divided by average assets (average of assets at the beginning of the year and at the year's end). This metric helps investors understand how effectively a company is using its assets to generate sales. For example, a sales-to-assets ratio of 2.5 indicates that the company generated \$2.50 in sales for every \$1 of assets on its books.

The higher the sales-to-assets ratio, the better the company is performing. However, similar to many other ratios, the asset turnover ratio tends to be higher for companies in certain industries/sectors than in others. So, a company's sales-to-assets ratio should be compared with the same for its industry/sector.

**Historical EPS Growth (3-5 Years):** This is the average annual (trailing-12-month) EPS growth rate over the last 3-5 years. This metric helps investors see how a company's EPS has grown from a long-term perspective.

Note: There are many factors that can influence short-term numbers — a recession will reduce this number, while a recovery will inflate it. The longterm perspective helps smooth out short-term events.

**Projected EPS Growth (F1/F0):** This is the estimated EPS growth rate for the current financial year. It is calculated as the consensus estimate for the current fiscal year (F1) divided by the reported EPS for the last completed fiscal year (F0).

**Current Cash Flow Growth:** It measures the latest year-over-year change in operating cash flow. Cash flow growth tells an investor how quickly a company is generating inflows of cash from operations. A positive change in the cash flow is desired and shows that more 'cash' is coming in than going out.

**Historical Cash Flow Growth (3-5 Years):** This is the annualized change in cash flow over the last 3-5 years. The change in a longer period helps put the current reading into proper perspective. By looking at the rate, rather than the actual dollar value, the comparison across the industry and peers becomes easier.

**Projected Sales Growth (F1/F0):** This metric looks at the estimated sales growth for the current year. It is calculated as sales estimate for the current fiscal year (F1) divided by the reported sales for the last completed fiscal year (F0).

Like EPS growth, a higher rate is better for sales growth. A look at a company's projected sales growth instantly tells you what the outlook is for their products and services. However, different sales growth rates are considered good for different industries, so it's better to compare sales growth rates of companies in the same industry group.

**EPS F1 Estimate 1-Week Change:** The percentage change in the Zacks Consensus EPS estimate for the current fiscal year over the past week. The change in a company's consensus EPS estimate (or earnings estimate revision) has proven to be strongly correlated with the near-term price movement of its shares. It is an integral part of the Zacks Rank.

If a stock's consensus EPS estimate is \$1.10 now versus \$1.00 a week ago, that will be reflected as a 10% upward revision. If, on the other hand, it went from \$1.00 to 90 cents, that would be a 10% downward revision.

**EPS F1 Estimate 4-Week Change:** The percentage change in the Zacks Consensus EPS estimate for the current fiscal year over the past four weeks.

A stock's earnings estimate revision in a 1-week period is important. But it's more meaningful to look at the longer-term revision. And, of course, the 4-week change helps put the 1-week change into proper perspective.

**EPS F1 Estimate 12-Week Change:** The percentage change in the Zacks Consensus EPS estimate for the current fiscal year over the past 12 weeks.

This metric essentially shows how the consensus EPS estimate has changed over a period longer than 1 week or 4 weeks.

**EPS Q1 Estimate Monthly Change:** The percentage change in the Zacks Consensus EPS estimate for the current fiscal quarter over the past four weeks.

While the revision in consensus EPS estimate for the current fiscal year is strongly correlated with the near-term price movement of its shares, the estimate revision for the current fiscal quarter is an important metric as well, especially over the short term, and particularly as a stock approaches its earnings date. If a stock's Q1 EPS estimate decreases ahead of its earnings release, it's usually a negative sign, whereas an increase is a positive sign.